Get started
Author

Thomas B. Neff

Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
2019 · Nan Chen, Chuanming Hao, et al. · New England Journal of Medicine · 622
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
2019 · Nan Chen, Chuanming Hao, et al. · New England Journal of Medicine · 581
PDF
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
2019 · Luca Richeldi, Evans R Fernández Pérez, et al. · The Lancet Respiratory Medicine · 291
Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
2016 · Robert Provenzano, Anatole Besarab, et al. · Clinical Journal of the American Society of Nephrology · 290
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
2015 · Anatole Besarab, Robert Provenzano, et al. · Nephrology Dialysis Transplantation · 286
PDF
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
2016 · Robert Provenzano, Anatole Besarab, et al. · American Journal of Kidney Diseases · 263
Roxadustat (FG-4592)
2015 · Anatole Besarab, Elena Chernyavskaya, et al. · Journal of the American Society of Nephrology · 250
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
2017 · Nan Chen, Jiaqi Qian, et al. · Nephrology Dialysis Transplantation · 205
Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria
2010 · Sharon G. Adler, Sherwyn Schwartz, et al. · Clinical Journal of the American Society of Nephrology · 204
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis
2016 · Ganesh Raghu, Mary Beth Scholand, et al. · European Respiratory Journal · 175
PDF
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis
2021 · Robert Provenzano, Evgeny Shutov, et al. · Nephrology Dialysis Transplantation · 136
Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD
2021 · Robert Provenzano, Lynda Szczech, et al. · Clinical Journal of the American Society of Nephrology · 89
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease
2020 · Ughetta del Balzo, Pierre E. Signore, et al. · Journal of Pharmacology and Experimental Therapeutics · 67
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer
2017 · Todd W Seeley, Mark D Sternlicht, et al. · Hypoxia · 54
PDF
RETRACTED: Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
2020 · Robert Provenzano, Steven Fishbane, et al. · Kidney International Reports · 36
PDF
Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
2020 · Robert Provenzano, James Tumlin, et al. · The Journal of Clinical Pharmacology · 29
PDF
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
2017 · Vincent J. Picozzi, Flavio G. Rocha, et al. · Journal of Clinical Oncology · 11
253 Evaluation of FG-4592, a Novel Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, to Treat Anemia in Hemodialysis Patients
2011 · Robert Provenzano, David Goodkin, et al. · American Journal of Kidney Diseases · 11
212: FG2216, A Novel Oral HIF-PHI, Stimulates Erythropoiesis and Increases Hemoglobin Concentration in Patients with Non-Dialysis CKD
2008 · R. Provenzano, G. Fadda, et al. · American Journal of Kidney Diseases · 11
FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
2016 · Vincent J. Picozzi, J. Marc Pipas, et al. · Cancer clinical trials · 8
A phase I trial of the monoclonal antibody FG-3019 to connective tissue growth factor (CTGF) in locally advanced or metastatic pancreatic cancer.
2011 · G. M. Heestand, J. M. Pipas, et al. · Journal of Clinical Oncology · 7
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
2016 · Vincent J. Picozzi, Flavio G. Rocha, et al. · Journal of Clinical Oncology · 3
Effect of pamrevlumab on the UCSD-SOBQ (University of California San Diego–Shortness of Breath Questionnaire) in patients with Idiopathic Pulmonary Fibrosis (IPF)
2018 · Eduard Gorina, Tro Sekayan, et al. · 2
254 Pharmacokinetics of Oral FG-4592 to Treat Anemia in Hemodialysis (HD) Patients (PTS)
2011 · Robert Provenzano, James Tumlin, et al. · American Journal of Kidney Diseases · 2
Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623
2022 · Robert Provenzano, Steven Fishbane, et al. · Kidney International Reports · 1
Works count: 33
Citation count: 3,632
H-index: 16
I10-index: 19
Year
Topic
Type